Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 5,000 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $16.49, for a total transaction of $82,450.00. Following the sale, the chief executive officer now owns 972,892 shares of the company’s stock, valued at approximately $16,042,989.08. This represents a 0.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Samuel Kintz also recently made the following trade(s):

• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.08, for a total transaction of $107,026.40.
• On Thursday, April 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00.
• On Monday, March 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00.

Enliven Therapeutics Stock Performance

ELVN stock opened at $16.93 on Thursday. The stock has a market capitalization of $830.74 million, a PE ratio of -8.91 and a beta of 1.07. The company has a fifty day moving average of $18.62 and a 200-day moving average of $21.52. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). Equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. HC Wainwright boosted their price target on Enliven Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 15th. Jones Trading dropped their target price on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $37.25.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently modified their holdings of the business. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after buying an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC purchased a new position in Enliven Therapeutics in the fourth quarter worth $15,106,000. Janus Henderson Group PLC lifted its holdings in Enliven Therapeutics by 27.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock valued at $30,001,000 after acquiring an additional 290,153 shares during the period. FMR LLC lifted its holdings in Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock valued at $146,157,000 after acquiring an additional 199,692 shares during the period. Finally, Pictet Asset Management Holding SA boosted its position in shares of Enliven Therapeutics by 16.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.